false 0001213660 0001213660 2023-11-29 2023-11-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 29, 2023

 

BIMI International Medical Inc.
(Exact name of registrant as specified in its charter)

 

Delaware   001-34890   02-0563302
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

725 5th Avenue, 15th Floor, 15-01

New York NY

  10022
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 212 542 0028

 

     
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.001 par value   BIMI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 4.01 Changes in Registrant’s Certifying Accountant.

 

Previous independent registered public accounting firm

 

On November 29, 2023, we informed Audit Alliance LLP (“AA”) of the determination to release AA as our independent accounts, effective immediately. This decision was approved and ratified by our board of directors on November 30, 2023.

 

AA was first engaged by us on September 10, 2020 and has rendered reports on our financial statements for the years ended December 31, 2020, 2021, and 2022. For the year ended December 31, 2020 and through the date of this form 8-K, AA has neither provided any adverse opinion or qualifications on our financial statements nor had a disagreement with the Company since their engagement on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements that, if not resolved to AA’s satisfaction, would have caused AA to make reference to the subject matter of the disagreement in connection with the audit of the Company’s financial statements.

 

None of the reportable events described under Item 304(a)(1)(v)(A)-(D) of Regulation S-K occurred within period of the engagement of AA up to the date of dismissal.

 

We have provided AA with a copy of this report prior to its filing with the Securities and Exchange Commission (the “SEC”). AA has provided a letter to us, dated December 4, 2023 and addressed to the SEC, which is attached hereto as Exhibit 16.1 and is hereby incorporated herein by reference.

 

New independent registered public accounting firm

 

We have engaged Enrome LLP (“Enrome”) as our independent registered public accounting firm, effective November 30, 2023, for our fiscal year ended December 31, 2023. The decision to engage Enrome as our independent registered public accounting firm was approved by our audit committee and board of directors on November 30, 2023.

 

During the two most recent fiscal years and through the date of this report, we have not consulted with Enrome regarding any of the following:

 

1.       the application of accounting principles to any specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our financial statements;

 

2.       the type of audit opinion that might be rendered on the Company’s financial statements by Enrome, in either case where written or oral advice provided by Enrome would be an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issues; or

 

3.       any matter that was either the subject of a disagreement (as defined in paragraph (a)(1)(iv) of Item 304 of Regulation S-K and the related instructions thereto) or a reportable event (as described in paragraph (a)(1)(v) of Item 304 of Regulation S-K).

 

Item 9.01. Financial Statement and Exhibits.

 

Exhibit No   Document
16.1   Consent Letter of Audit Alliance LLP dated December 4, 2023

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: December 4, 2023 BIMI International Medical Inc.
   
  By: /s/ Tiewei Song
  Name: Tiewei Song
  Title: Chief Executive Officer

 

 

2

 

 

Exhibit 16.1

 

 

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We have read the statements under Item 4.01 in the Current Report on Form 8-K dated December 4, 2023 (the “8-K”), of BIMI International Medical Inc (the “Company”) to be filed with the Securities and Exchange Commission and we agree with such statements therein as related to our firm. We have no basis, and therefore, do not agree or disagree with the other statements made by the Company in the 8-K.

 

/s/ AuditAlliance LLP

 

Singapore

December 4,2023

 

v3.23.3
Cover
Nov. 29, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 29, 2023
Entity File Number 001-34890
Entity Registrant Name BIMI International Medical Inc.
Entity Central Index Key 0001213660
Entity Tax Identification Number 02-0563302
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 725 5th Avenue
Entity Address, Address Line Two 15th Floor
Entity Address, Address Line Three 15-01
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10022
City Area Code 212
Local Phone Number 542 0028
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value
Trading Symbol BIMI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more BIMI International Medical Charts.
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more BIMI International Medical Charts.